See more : Exact Sciences Corporation (EXAS) Income Statement Analysis – Financial Results
Complete financial analysis of ALX Oncology Holdings Inc. (ALXO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ALX Oncology Holdings Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- American Overseas Group Limited (AOREF) Income Statement Analysis – Financial Results
- SAS AB (publ) (SAS-DKK.CO) Income Statement Analysis – Financial Results
- Lida Resources Inc. (LDDAF) Income Statement Analysis – Financial Results
- ECP Environmental Growth Opportunities Corp. (ENNV) Income Statement Analysis – Financial Results
- PION Group AB (publ) (PION-B.ST) Income Statement Analysis – Financial Results
ALX Oncology Holdings Inc. (ALXO)
About ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 1.18M | 4.80M | 2.07M |
| Cost of Revenue | 836.00K | 1.47M | 736.00K | 1.08M | 4.36M | 1.88M |
| Gross Profit | -836.00K | -1.47M | -736.00K | 107.00K | 436.00K | 187.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 9.05% | 9.09% | 9.05% |
| Research & Development | 141.80M | 98.40M | 60.17M | 28.96M | 16.31M | 11.27M |
| General & Administrative | 28.48M | 29.04M | 23.39M | 14.81M | 3.31M | 2.60M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 28.48M | 29.04M | 23.39M | 14.81M | 3.31M | 2.60M |
| Other Expenses | 0.00 | -260.00K | 84.00K | -404.00K | -5.00K | -2.00K |
| Operating Expenses | 170.28M | 127.44M | 83.56M | 43.77M | 19.62M | 13.87M |
| Cost & Expenses | 170.28M | 127.44M | 83.56M | 44.85M | 23.98M | 15.75M |
| Interest Income | 10.65M | 4.04M | 91.00 | 124.00K | 21.00 | 0.00 |
| Interest Expense | 1.57M | 0.00 | 13.00K | 811.00K | 21.00K | 0.00 |
| Depreciation & Amortization | 836.00K | 1.47M | 736.00K | 202.00K | 429.00K | 431.00K |
| EBITDA | -158.40M | -121.95M | -83.47M | -43.46M | -18.76M | -13.26M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -3,728.17% | -391.14% | -641.27% |
| Operating Income | -170.28M | -127.44M | -83.56M | -43.66M | -19.18M | -13.68M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -3,693.99% | -399.98% | -662.02% |
| Total Other Income/Expenses | 9.47M | 4.02M | 71.00K | -1.84M | -26.00K | -2.00K |
| Income Before Tax | -160.81M | -123.42M | -83.48M | -45.50M | -19.21M | -13.69M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -3,849.32% | -400.52% | -662.12% |
| Income Tax Expense | 0.00 | 64.00K | -21.00K | 241.00K | 34.00K | 45.00K |
| Net Income | -160.81M | -123.48M | -83.46M | -45.74M | -19.24M | -13.73M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -3,869.71% | -401.23% | -664.30% |
| EPS | -3.74 | -3.03 | -2.07 | -1.15 | -0.53 | -0.63 |
| EPS Diluted | -3.74 | -3.03 | -2.07 | -1.15 | -0.53 | -0.63 |
| Weighted Avg Shares Out | 42.99M | 40.70M | 40.31M | 39.84M | 36.49M | 21.95M |
| Weighted Avg Shares Out (Dil) | 42.99M | 40.70M | 40.31M | 39.84M | 36.49M | 21.95M |
ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation
Down -30.79% in 4 Weeks, Here's Why ALX Oncology Holdings (ALXO) Looks Ripe for a Turnaround
Source: https://incomestatements.info
Category: Stock Reports